irblog.prnewswire.com

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug ...
Healio

BLOG: Unexpected present, positive results

Please provide your email address to receive an email when new articles are posted on . During a most unexpected and challenging year, ophthalmic practices are looking for reasons to celebrate. The ...
Healio

Perspective: I. Paul Singh, MD, on the FDA approval of Durysta

Please provide your email address to receive an email when new articles are posted on . The recent paradigm shift in the treatment of glaucoma moving toward earlier intervention, better managing ...
Nasdaq

Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in ...

- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies - - Allergan continues five ongoing ...